1. Scrip

The Viren Mehta Column: Disrupt Or Be Disrupted

 
• By Viren Mehta

In the first of an exclusive new opinion column series for Scrip, Viren Mehta, founder of Mehta Partners, LLC, considers how the digital revolution will transform the pharma industry whether or not companies in the space decide to play along.

Dinosaurs
Pharma dinosaurs need to consider evolution • Source: Shutterstock

The 21st century ushered in an age where raw data and deep analytic intelligence are transforming practically every aspect of our society. But biopharma managements remain understated in their public commentary on the implications of IT for their business prospects. To date, regulatory barriers and divided stakeholder interests have given the biopharma industry reasons for not addressing the IT frontier head-on, but tech pioneers can see major opportunities and will not be held back forever.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from R&D

More from Scrip

Zepbound Grows, But CVS/Novo Nordisk Deal For Wegovy Casts Shadow

 
• By Alaric DeArment

Lilly executives told the company’s Q1 call they were not surprised at the Wegovy deal, but some analysts said it could cut into prescription growth for Zepbound.

Scrip M&A Podcast: Will FDA Staff Cuts Impact Biopharma Dealmaking?

 
• By Joseph Haas

Attorneys Andrew Goodman and Alan Minsk, as well as Naya CEO Daniel Teper, discussed the ramifications of US FDA staff cuts on M&A activity with Scrip senior writer Joseph Haas.

Could There Be A Cure For Cardiometabolic Disease? Novo Nordisk Foundation Wants To Help Academics Find Out

 
• By Andrew McConaghie

The not-for-profit’s senior vice president Martin Ridderstråle explains how it is expanding grants for basic research to improve "human and planetary" health.